Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 11 - Drugs for disorders of the respiratory system
Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
10/2001
10/10/2001EP1142867A2 Cell adhesion inhibitors
10/10/2001EP1141728A1 Kidney disease detection and treatment
10/10/2001EP1141342A2 Use of plus-strand synthesis elements in retroviral vectors
10/10/2001EP1141339A1 Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
10/10/2001EP1141332A1 Human cyclic nucleotide pdes
10/10/2001EP1141325A1 Ikk3 kinase
10/10/2001EP1141306A2 Streptococcus antigens
10/10/2001EP1141288A2 Lymphocytic membrane proteins
10/10/2001EP1141286A1 Cytokine receptor chain
10/10/2001EP1141278A2 Therapeutic phosphodiesterase inhibitors
10/10/2001EP1141274A2 Soluble receptor br43x2 and methods of using them for therapy
10/10/2001EP1141266A2 Expression vectors comprising multiple shear stress responsive elements (ssre) and a gene of interest and methods of use thereof
10/10/2001EP1141024A2 Polypeptide variants with altered effector function
10/10/2001EP1141020A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof
10/10/2001EP1141015A1 Insulin-like growth factor (igf) i mutant variants
10/10/2001EP1141011A2 Compounds and methods to inhibit or augment an inflammatory response
10/10/2001EP1140998A1 $i(CHLAMYDIA) ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF
10/10/2001EP1140984A1 Selective inhibitors of mmp-12
10/10/2001EP1140969A1 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001EP1140964A2 Connective tissue growth factor fragments and methods and uses thereof
10/10/2001EP1140945A1 Fused 1,2,4-thiadiazine derivatives, their preparation and use
10/10/2001EP1140943A2 Substituted pyrroloindoles
10/10/2001EP1140939A1 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidines, and related pharmaceutical compositions and methods
10/10/2001EP1140924A1 Piperazine derivatives
10/10/2001EP1140923A1 Method for preparing (r)- (+) -3 1- 2-( 4-benzoyl- 2-(3,4- difluorophenyl)morpholin- 2-yl)ethyl]- 4-phenylpiperidin -4-yl -1,1- dimethylurea, its salts solvates and/or hydrates
10/10/2001EP1140920A1 Piperidines as ccr5 modulators
10/10/2001EP1140916A1 Heteroaryl-cyclic acetals
10/10/2001EP1140914A1 Non-peptide nk1 receptors antagonists
10/10/2001EP1140873A1 Il-5 inhibiting 6-azauracil derivatives
10/10/2001EP1140837A1 Compounds useful in the treatment of inflammatory diseases
10/10/2001EP1140835A1 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
10/10/2001EP1140821A1 Lactams
10/10/2001EP1140792A1 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
10/10/2001EP1140784A2 Ion channel modulating agents
10/10/2001EP1140768A1 Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases
10/10/2001EP1140205A2 GENE THERAPY FOR PULMONARY EDEMA USING ADENOVIRUS VECTORS ENCODING Na,K-ATPase
10/10/2001EP1140202A1 Peptidic product, process and composition
10/10/2001EP1140194A2 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combined treatment of neoplasia
10/10/2001EP1140193A2 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
10/10/2001EP1140192A2 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
10/10/2001EP1140183A1 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
10/10/2001EP1140182A2 Use of a matrix metalloproteinase inhibitor together with an antineoplastic agent, optionally also together with radiation, in the treatment of neoplasia
10/10/2001EP1140179A2 Use of a cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
10/10/2001EP1140178A2 Use of a matrix metallaproteinase inhibitor and radiation as a combined treatment of neoplasia
10/10/2001EP1140177A2 Use of an integrin antagonist and radiation in the treatment of neoplasia
10/10/2001EP1140175A2 Antibodies to truncated vegf-d and uses thereof
10/10/2001EP1140173A2 Vascular endothelial cell growth factor antagonists and uses thereof
10/10/2001EP1140171A1 Methods and products for regulating lectin complement pathway associated complement activation
10/10/2001EP1140150A2 Method for accelerating the rate of mucociliary clearance by using a kunitz-type serine protease inhibitor
10/10/2001EP1140138A2 Therapeutic applications of flint polypeptides
10/10/2001EP1140113A2 Use of bisphosphonates for the prevention and treatment of infectious processes
10/10/2001EP1140112A1 Use of etherlysophospholipids as antiinflammatory agents
10/10/2001EP1140098A2 Tricyclic nitrogen heterocycles as pde iv inhibitors
10/10/2001EP1140095A1 (2-imidazoline-2-ylamino) quinoxaline derivatives for the treatment of pain
10/10/2001EP1140093A2 Compositions having improved delivery of actives
10/10/2001EP1140085A1 Azabicycloalkanes as ccr5 modulators
10/10/2001EP1140083A1 Novel compounds
10/10/2001EP1140077A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
10/10/2001EP1140076A1 Use of 5ht3-receptor antagonists for the treatment of chronic fatigue syndrome
10/10/2001EP1140072A1 Compounds and methods
10/10/2001EP1140071A1 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
10/10/2001EP1140069A1 COMPOUNDS WHICH AFFECT mRNA STABILITY AND USES THEREFOR
10/10/2001EP1140062A2 Treatment of asthma with mek inhibitors
10/10/2001EP1140055A1 Use of a 5ht 2a? and 5ht 2a/c? receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways
10/10/2001EP1140048A2 Methods for treating certain diseases using naaladase inhibitors
10/10/2001EP1140021A1 Improved formulation for topical non-invasive application in vivo
10/10/2001EP1139913A1 Composition and formulations and their use as nociceptic, anti-anxiolytic and anabolic agents
10/10/2001EP1139755A2 Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
10/10/2001EP1139746A1 Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
10/10/2001EP0840620B1 Il-8 antagonists for treatment of asthma
10/10/2001EP0764163B1 Tachykinin (nk 1) receptor antagonists
10/10/2001CN1317015A Human anti-factor IX/IXa antibodies
10/10/2001CN1316998A Thiobenzimidazole derivatives
10/10/2001CN1316995A Hydroxy 2-pipecolate hydroxamide acid derivatives as MMP inhititors
10/10/2001CN1316993A 4,4-biarylpiperidime derivatives with opioid receptor activity
10/10/2001CN1316991A Azetidine derivatives, preparation and medicines containing them
10/10/2001CN1316906A Stable liquid formulations of botulinum toxin
10/10/2001CN1316261A Chinese-medical buccal lozenge and its preparing process
10/10/2001CN1316251A Capsule for treating nasosimusitis
10/10/2001CN1072666C (Azetidin-1-ylalkyl) lactams as tachykinin antagonists
10/10/2001CN1072664C Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compound
10/10/2001CN1072493C Compound asthma capsule and its preparation method
10/09/2001US6300376 Indane dimer compounds and their pharmaceutical use
10/09/2001US6300359 (E)-3-[1-n-Butyl-5-[2-(2-carboxyphenyl)methoxy-4-chlorophenyl]-1H-pyrazol-4-yl]-2-[(5-methoxy-2,3-dihydrobenzofuran-6-yl)methyl]-prop-2-enoic acid monoargininyl salt
10/09/2001US6300350 Administering to mammal an retinoic acid (rar) agonist that is at least gamma selective and is rar.alpha. sparing for treating emphysema
10/09/2001US6300334 Thieno[2,3-d]pyrimidine-2,4-diones
10/09/2001US6300332 Methods for reducing respiratory depression and attendant side effects of mu opioid compounds
10/09/2001US6300325 Heterocyclic receptor antagonist
10/09/2001US6300317 Eukarotic cells, polynucleotide, functional agents, membrane permeability, subcellar localization agents and polynucleotide masking agents
10/09/2001US6299897 Attaching selectin binding carbohydrate to a cross-linkable lipid; attaching an acidic group to a cross linkable lipid; forming lipids into sheet; crosslinking lipids
10/09/2001US6299888 Azelastine hydrochloride-containing percutaneous preparation having good percutaneous absorbability and reduced skin irritation
10/09/2001US6299861 Administering aerosol of inhalable ipratropium bromide for inhibiting acetylcholine induced bronchospasm in humans
10/07/2001CA2304906A1 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/04/2001WO2001073034A2 Beta-like glycoprotein hormone polypeptide and heterodimer
10/04/2001WO2001073029A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
10/04/2001WO2001073018A2 Human tap-like protein (transporter associated in antigen processing/presentation)
10/04/2001WO2001072960A2 Il-8 receptor antagonists
10/04/2001WO2001072846A2 Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof
10/04/2001WO2001072839A2 Human g-protein coupled receptors
10/04/2001WO2001072836A2 G-protein coupled receptors
1 ... 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 ... 878